158 related articles for article (PubMed ID: 22030030)
21. Design and synthesis of 4-alkynyl pyrazoles as inhibitors of PDE4: a practical access via Pd/C-Cu catalysis.
Gorja DR; Shiva Kumar K; Kandale A; Meda CL; Parsa KV; Mukkanti K; Pal M
Bioorg Med Chem Lett; 2012 Apr; 22(7):2480-7. PubMed ID: 22381049
[TBL] [Abstract][Full Text] [Related]
22. Conformationally restricted novel pyrazole derivatives: synthesis of 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles as a new class of PDE4 inhibitors.
Reddy TS; Kumar KS; Meda CL; Kandale A; Rambabu D; Krishna GR; Hariprasad C; Rao VV; Venkataiah S; Reddy CM; Naidu A; Dubey PK; Parsa KV; Pal M
Bioorg Med Chem Lett; 2012 May; 22(9):3248-55. PubMed ID: 22464134
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
Taltavull J; Serrat J; Gràcia J; Gavaldà A; Córdoba M; Calama E; Montero JL; Andrés M; Miralpeix M; Vilella D; Hernández B; Beleta J; Ryder H; Pagès L
Eur J Med Chem; 2011 Oct; 46(10):4946-56. PubMed ID: 21871695
[TBL] [Abstract][Full Text] [Related]
24. Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation.
Hamza A; Zhan CG
J Phys Chem B; 2009 Mar; 113(9):2896-908. PubMed ID: 19708117
[TBL] [Abstract][Full Text] [Related]
25. Novel thieno[2,3-d]pyrimidines: their design, synthesis, crystal structure analysis and pharmacological evaluation.
Adepu R; Rambabu D; Prasad B; Meda CL; Kandale A; Krishna GR; Reddy CM; Chennuru LN; Parsa KV; Pal M
Org Biomol Chem; 2012 Aug; 10(29):5554-69. PubMed ID: 22710638
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells.
Mareddy J; Nallapati SB; Anireddy J; Devi YP; Mangamoori LN; Kapavarapu R; Pal S
Bioorg Med Chem Lett; 2013 Dec; 23(24):6721-7. PubMed ID: 24215890
[TBL] [Abstract][Full Text] [Related]
27. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
[TBL] [Abstract][Full Text] [Related]
28. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
29. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Hamblin JN; Angell TD; Ballantine SP; Cook CM; Cooper AW; Dawson J; Delves CJ; Jones PS; Lindvall M; Lucas FS; Mitchell CJ; Neu MY; Ranshaw LE; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2008 Jul; 18(14):4237-41. PubMed ID: 18539455
[TBL] [Abstract][Full Text] [Related]
30. Molecular Bases of PDE4D Inhibition by Memory-Enhancing GEBR Library Compounds.
Prosdocimi T; Mollica L; Donini S; Semrau MS; Lucarelli AP; Aiolfi E; Cavalli A; Storici P; Alfei S; Brullo C; Bruno O; Parisini E
Biochemistry; 2018 May; 57(19):2876-2888. PubMed ID: 29652483
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, biological evaluation and structural characterization of novel GEBR library PDE4D inhibitors.
Brullo C; Rapetti F; Abbate S; Prosdocimi T; Torretta A; Semrau M; Massa M; Alfei S; Storici P; Parisini E; Bruno O
Eur J Med Chem; 2021 Nov; 223():113638. PubMed ID: 34171658
[TBL] [Abstract][Full Text] [Related]
32. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.
Ochiai K; Takita S; Kojima A; Eiraku T; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2013 Jan; 23(1):375-81. PubMed ID: 23200255
[TBL] [Abstract][Full Text] [Related]
33. Montmorillonite K-10 mediated green synthesis of cyano pyridines: Their evaluation as potential inhibitors of PDE4.
Ram Reddy T; Rajeshwar Reddy G; Srinivasula Reddy L; Jammula S; Lingappa Y; Kapavarapu R; Meda CL; Parsa KV; Pal M
Eur J Med Chem; 2012 Feb; 48():265-74. PubMed ID: 22217868
[TBL] [Abstract][Full Text] [Related]
34. Diastereoselective synthesis and profiling of bicyclic imidazolidinone derivatives bearing a difluoromethylated catechol unit as potent phosphodiesterase 4 inhibitors.
Dorokhov VS; Golovanov IS; Tartakovsky VA; Sukhorukov AY; Ioffe SL
Org Biomol Chem; 2018 Oct; 16(38):6900-6908. PubMed ID: 30024008
[TBL] [Abstract][Full Text] [Related]
35. Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.
Felding J; Sørensen MD; Poulsen TD; Larsen J; Andersson C; Refer P; Engell K; Ladefoged LG; Thormann T; Vinggaard AM; Hegardt P; Søhoel A; Nielsen SF
J Med Chem; 2014 Jul; 57(14):5893-903. PubMed ID: 24984230
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, Anti-inflammatory Activity and Docking Studies of Some Newer 1,3-Thiazolidine-2,4-dione Derivatives as Dual Inhibitors of PDE4 and PDE7.
Sharma H; Lather V; Grewal AS; Pandita D
Curr Comput Aided Drug Des; 2019; 15(3):225-234. PubMed ID: 30280674
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 2-(3,4-dialkoxyphenyl)-2-(substituted pyridazin-3-yl)acetonitriles as phosphodiesterase 4 inhibitors with anti-neuroinflammation potential based on three-dimensional quantitative structure-activity relationship study.
Huang C; Zhong QP; Tang L; Wang HT; Xu JP; Zhou ZZ
Chem Biol Drug Des; 2019 Apr; 93(4):484-502. PubMed ID: 30588755
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors.
Poondra RR; Nallamelli RV; Meda CL; Srinivas BN; Grover A; Muttabathula J; Voleti SR; Sridhar B; Pal M; Parsa KV
Bioorg Med Chem Lett; 2013 Feb; 23(4):1104-9. PubMed ID: 23294698
[TBL] [Abstract][Full Text] [Related]
39. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center.
Freund YR; Akama T; Alley MR; Antunes J; Dong C; Jarnagin K; Kimura R; Nieman JA; Maples KR; Plattner JJ; Rock F; Sharma R; Singh R; Sanders V; Zhou Y
FEBS Lett; 2012 Sep; 586(19):3410-4. PubMed ID: 22841723
[TBL] [Abstract][Full Text] [Related]
40. Pharmacophore modeling and virtual screening for the discovery of new type 4 cAMP phosphodiesterase (PDE4) inhibitors.
Niu M; Dong F; Tang S; Fida G; Qin J; Qiu J; Liu K; Gao W; Gu Y
PLoS One; 2013; 8(12):e82360. PubMed ID: 24340020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
